K Number
K171820
Device Name
Transjugular Liver Access Sets
Manufacturer
Date Cleared
2018-03-09

(263 days)

Product Code
Regulation Number
870.1340
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Rosch-Uchida Transjugular Liver Access Set is intended for transjugular liver access in diagnostic and interventional procedures. The Ring Transjugular Intrahepatic Access Set is intended for transjugular liver access in diagnostic and interventional procedures.
Device Description
The Transjugular Liver Access Sets are comprised of various components that facilitate transjugular access to the liver for the purpose of performing diagnostic and interventional procedures. The sets are grouped into two basic types: the Ring Transjugular Intrahepatic Access Set and the Rösch-Uchida Transjugular Liver Access Set. Each set includes a core component comprised of a combination of either a stiffening cannula/Teflon catheter or needle stylet/Teflon catheter that facilitates access into the hepatic vasculature and the creation of a pathway into the portal vein. Other components included in some of these sets are a Check-Flo Introducer Set. selective catheters, and wire guides.
More Information

No
The device description and performance studies focus on the physical components and their mechanical properties, with no mention of software, algorithms, or data processing that would indicate AI/ML. The "Mentions AI, DNN, or ML" field is explicitly marked as "Not Found".

No
This device is an access set used to facilitate procedures, not to treat a disease or condition itself.

Yes

Explanation: The "Intended Use / Indications for Use" section explicitly states that the device is "intended for transjugular liver access in diagnostic and interventional procedures." This indicates that diagnostic use is one of its primary functions.

No

The device description explicitly states it is comprised of various components including cannulas, catheters, needle stylets, introducer sets, selective catheters, and wire guides, which are all physical hardware components. The performance studies also detail testing on these physical components.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use is for "transjugular liver access in diagnostic and interventional procedures." This describes a procedure performed on the patient to gain access to an internal organ, not a test performed on a sample taken from the patient.
  • Device Description: The device components are described as facilitating access into the hepatic vasculature and creating a pathway. These are tools for a medical procedure, not reagents or instruments for analyzing biological samples.
  • Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, tissue, etc.), detecting specific analytes, or providing diagnostic information based on laboratory testing. The "diagnostic procedures" mentioned in the intended use refer to procedures like angiography or biopsy performed through the access created by the device, not the device itself performing a diagnostic test.

Therefore, the Rosch-Uchida Transjugular Liver Access Set and the Ring Transjugular Intrahepatic Access Set are medical devices used for surgical/interventional procedures, not in vitro diagnostic devices.

N/A

Intended Use / Indications for Use

The Rosch-Uchida Transjugular Liver Access Set is intended for transjugular liver access in diagnostic and interventional procedures.

The Ring Transjugular Intrahepatic Access Set is intended for transjugular liver access in diagnostic and interventional procedures.

Product codes (comma separated list FDA assigned to the subject device)

DYB

Device Description

The Transjugular Liver Access Sets are comprised of various components that facilitate transjugular access to the liver for the purpose of performing diagnostic and interventional procedures. The sets are grouped into two basic types: the Ring Transjugular Intrahepatic Access Set and the Rösch-Uchida Transjugular Liver Access Set. Each set includes a core component comprised of a combination of either a stiffening cannula/Teflon catheter or needle stylet/Teflon catheter that facilitates access into the hepatic vasculature and the creation of a pathway into the portal vein. Other components included in some of these sets are a Check-Flo Introducer Set. selective catheters, and wire guides. The following components of the subject device sets have received prior 510(k) clearance: the Flexor Check-Flo Introducer Set (K142829), the van Andel Catheter (K170616), and the Torcon NB Advantage Catheter (K161822). Each component is individually packaged in an inner Tyvek pouch. All inner pouches for a given set configuration are packaged within an outer Tyvek pouch.

The Ring Transjugular Intrahepatic Access Set's core component is a Colapinto Needle and Catheter Assembly. The Colapinto Needle is a hollow 16 gage stainless steel stiffening cannula with a needle bevel and a length of 50.5 cm. It is matched with either a 9 Fr or 10 Fr Teflon catheter. The Rösch-Uchida Transjugular Liver Access Set's core component is a Stylet and Catheter Assembly that functions coaxially with a stiffening access cannula which provides access and support for the needle stylet/catheter assembly. The stylet is a 0.038 inch diameter stainless steel trocar with a length of 62.5 cm. It is matched with a 5.2 Fr Teflon catheter. The stiffening access cannula is a hollow 14 gage stainless steel tube with a length of 54.5 cm that is matched with 10 Fr Teflon catheter.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

transjugular liver

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Performance and biocompatibility testing was conducted in accordance with applicable FDA guidance documents to confirm the reliable performance of critical device characteristics. Testing on specific introducer and catheter components (the Van Andel Catheter, the Torcon NB® Advantage Catheter, and the Flexor Check-Flo Introducer Set) is not included because these devices have been previously cleared by the FDA under 510(k) numbers K170616, K161822, and K142829, respectively.

Biocompatibility Testing - Per ISO 10993-1 and FDA guidance, testing for Cytotoxicity, Sensitization, Irritation, Acute Systemic Toxicity, Hemocompatibility (Hemolysis, Complement Activation, In Vivo Thrombogenicity), and Material-mediated Pyrogenicity tests were performed on all components of the subject device or on representative devices. All test results met the acceptance criteria, where applicable, or demonstrated that the device is biocompatible.

Performance Testing - The components in the subject device were subjected to applicable testing to assure reliable design and performance under the testing parameters. The tests for the core components (i.e., set components that puncture through the hepatic vein, liver parenchyma, and portal vein) and the accessories are listed below. In addition to the tests listed below, dimensional, surface and compatibility analysis was performed on all components in the subject device to verify that the critical dimensions met the predefined acceptance criteria, that the surfaces of the devices were from defects, and that the set components were compatible.

Testing performed on the core components includes the following:

  • Radiopacity Testing performed demonstrated that the devices were visible in the radiographic image and were qualitatively assessed to be non-inferior to the user-defined standard, following the method described in ASTM F640-12, "Standard Test Methods For Determining Radiopacity for Medical Use."
  • Corrosion Resistance Testing performed demonstrated that there is no effect on the functional performance of the components.
  • Tensile Testing performed on the components per applicable ISO and JIS standards demonstrated that the devices met the acceptance criteria.
  • Torque - Testing performed demonstrated that the peak torque was within the clinical requirement.
  • Liquid Leakage, Air Leakage and Burst Pressure Testing performed on catheter per the test method described in relevant annexes of ISO 10555-1:2013 met the acceptance criteria.
  • Resistance to Breakage Testing performed per the test method described in Annex C of BS EN ISO 9626 demonstrated that the test articles met the acceptance criteria.

Testing performed on the additional set components includes the following:

  • Dilator Hub-to-Shaft Tensile – Testing in accordance with BS EN ISO 11070 showed the peak load of the hub-to-shaft were greater than or equal to 15N.
  • Wire Guide Tensile Testing Testing in accordance with ISO 11070:2014, Annex H showed that the pre-determined acceptance criteria were met.
  • Wire Guide Corrosion Testing – Testing in accordance with Annex B of ISO 11070:2014 demonstrated that the pre-determined acceptance criteria were met.
  • Wire Guide Flexing Test – Testing in accordance with the Annex G of ISO 11070:2014 demonstrated that the pre-determined acceptance criteria were met.
  • Wire Guide Fracture Testing Testing in accordance with Annex F of ISO 11070:2014 demonstrated that the pre-determined acceptance criteria were met.
  • Wire Guide Torque Strength Testing - Characterization testing performed in accordance with the FDA Coronary and Cerebrovascular Guidewire Guidance (1995).
  • Wire Guide Tip Flexibility Characterization testing performed in accordance with the FDA Coronary and Cerebrovascular Guidewire Guidance (1995).

The results of testing provide reasonable assurance that the Transjugular Liver Access Sets have been designed so that they conform to the requirements of their intended use. The available evidence demonstrates that the subject devices are substantially equivalent to the predicate device, the GORE TIPS Set (K152913), and do not raise new questions of safety or effectiveness. This supports a determination of substantial equivalence.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

GORE TIPS Set (K152913)

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

K142829, K170616, K161822

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 870.1340 Catheter introducer.

(a)
Identification. A catheter introducer is a sheath used to facilitate placing a catheter through the skin into a vein or artery.(b)
Classification. Class II (performance standards).

0

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

March 9, 2018

Cook Incorporated Mr. David Lehr, RAC Regulatory Affairs Specialist 750 Daniels Way Bloomington, Indiana 47404

Re: K171820

Trade/Device Name: Transjugular Liver Access Sets Regulation Number: 21 CFR 870.1340 Regulation Name: Catheter Introducer Regulatory Class: Class II Product Code: DYB Dated: February 15, 2018 Received: February 16, 2018

Dear Mr. Lehr:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);

1

and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Kenneth J. Cavanaugh -S

for

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

2

Indications for Use

510(k) Number (if known) K171820

Device Name Transjugular Liver Access Sets

Indications for Use (Describe)

The Rosch-Uchida Transjugular Liver Access Set is intended for transjugular liver access in diagnostic and interventional procedures.

The Ring Transjugular Intrahepatic Access Set is intended for transjugular liver access in diagnostic and interventional procedures.

Type of Use (Select one or both, as applicable)
☑ Prescription Use (Part 21 CFR 801 Subpart D)☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

Image /page/3/Picture/0 description: The image shows the text 'K171820' in a simple, sans-serif font. The text is presented in a straightforward, unadorned manner, with each character clearly legible. The alphanumeric sequence appears to be a code or identifier, possibly a serial number or product code.

COOK INCORPORATED 750 DANIELS WAY, P.O. BOX 489 BLOOMINGTON, IN 47402-0489 U.S.A. PHONE: 812.339.2235 TOLL FREE: 800.457.4500 WWW.COOKMEDICAL.COM

510(k) SUMMARY

As required by 21 CFR §807.92 Date Prepared: February 14, 2018

I. SUBMITTER

Submission:Traditional 510(k) Premarket Notification
Applicant:Cook Incorporated
Contact:David Lehr, RAC
Applicant Address:Cook Incorporated
750 Daniels Way
Bloomington, IN 47404
Contact Phone Number:(812) 335-3575 ext. 102309
Contact Fax Number:(812) 332-0281

II. DEVICE

Trade Name: Common Name: Classification Name: Regulation/Class: Product Code

Transjugular Liver Access Sets Catheter Introducer Introducer, catheter 21 CFR §870.1340/Class II DYB

III. PREDICATE DEVICE

GORE TIPS Set (K152913), manufactured by Creganna Medical.

IV. DEVICE DESCRIPTION

The Transjugular Liver Access Sets are comprised of various components that facilitate transjugular access to the liver for the purpose of performing diagnostic and interventional procedures. The sets are grouped into two basic types: the Ring Transjugular Intrahepatic Access Set and the Rösch-Uchida Transjugular Liver Access Set. Each set includes a core component comprised of a combination of either a stiffening cannula/Teflon catheter or needle stylet/Teflon catheter that facilitates access into the hepatic vasculature and the creation of a pathway into the portal vein. Other components included in some of these sets are a Check-Flo Introducer Set. selective catheters, and wire guides. The following components of the subject device sets have received prior 510(k) clearance: the Flexor Check-Flo Introducer Set (K142829), the van Andel Catheter (K170616), and the Torcon NB Advantage Catheter (K161822). Each component is individually packaged in an inner Tyvek pouch. All inner pouches for a given set configuration are packaged within an outer Tyvek pouch.

The Ring Transjugular Intrahepatic Access Set's core component is a Colapinto Needle and Catheter Assembly. The Colapinto Needle is a hollow 16 gage stainless steel stiffening cannula

4

Cook Incorporated - Traditional 510(k) Transjugular Liver Access Sets February 14, 2018

with a needle bevel and a length of 50.5 cm. It is matched with either a 9 Fr or 10 Fr Teflon catheter. The Rösch-Uchida Transjugular Liver Access Set's core component is a Stylet and Catheter Assembly that functions coaxially with a stiffening access cannula which provides access and support for the needle stylet/catheter assembly. The stylet is a 0.038 inch diameter stainless steel trocar with a length of 62.5 cm. It is matched with a 5.2 Fr Teflon catheter. The stiffening access cannula is a hollow 14 gage stainless steel tube with a length of 54.5 cm that is matched with 10 Fr Teflon catheter.

V. INDICATIONS FOR USE

The Ring Transjugular Intrahepatic Access Set is intended for transjugular liver access in diagnostic and interventional procedures.

The Rösch-Uchida Transjugular Liver Access Set is intended for transjugular liver access in diagnostic and interventional procedures.

VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE

Cook's Transjugular Liver Access Sets and the predicate device, the GORE TIPS Set (K152913) manufactured by Creganna Medical, are substantially equivalent in that they have similar indications for use, technological characteristics, methods of construction, and principles of operation. The differences between the subject devices and the predicate device, including materials and component dimensions, were appropriately assessed and do not present any new questions of safety and/or effectiveness. Based on the comparison of the design, indications for use, materials, fundamental technology, and principles of operation, the subject devices are considered to be substantially equivalent to the currently marketed predicate device. The substantial equivalence comparison of the subject devices to the predicate is provided in the following table.

PREDICATE DEVICESUBJECT DEVICES
GORE TIPS Set
(K152913)Transjugular Liver Access Sets
ManufacturerCreganna MedicalCook Inc.
Regulation Number21 CFR §870.1340
Product CodeDYBIdentical
Classification NameIntroducer, Catheter
ClassII

Substantial Equivalence Comparison Table

5

Substantial Equivalence Comparison Table (continued)
----------------------------------------------------------------
PREDICATE DEVICESUBJECT DEVICE
GORE TIPS Set
(K152913)Transjugular Liver Access Sets
Indications for UseThe GORE TIPS Set, GORE
TIPS Sheath, and GORE TIPS
Needle are intended to be used
together for percutaneous
transjugular liver access during
diagnostic and interventional
procedures in patients
undergoing a Transjugular
Intrahepatic Portosystemic Shunt
(TIPS) procedure.Intended for transjugular liver
access in diagnostic and
interventional procedures.
Set components that puncture
through the hepatic vein, liver
parenchyma, and portal vein16 gage Stainless Steel Needle
  • 56 cm in length
    10 Fr MDPE catheter
  • 49 cm in length | 16 gage Stainless Steel Needle
  • 50.5 cm in length
    9 or 10 Fr Teflon Catheter
  • 45.5 cm in length
    OR
    0.038 inch Stainless Steel Needle
    Stylet
  • 62.5 cm in length
    5.2 Fr Teflon Catheter
  • 62 cm in length
    14 gage Stainless Steel
    Stiffening Access Cannula
  • 54.5 cm in length
    10 Fr Teflon Catheter
  • 51.8 cm in length |
    | Introducer Set | | |
    | Sheath Materials | PTFE liner, stainless steel coil
    Pebax 6333 Jacket | PTFE liner, stainless steel coil
    Nylon jacket |
    | Sheath Marker Band | Platinum/Iridium | Identical |
    | Sheath Hub Material | Grilamid | Nylon |
    | Sheath Outer Diameter (Fr) | 10 | 9, 10 |
    | Sheath Length (cm) | 40 | 38.5, 40 |
    | Dilator Material | HDPE | Polyethylene |
    | Dilator Hub Material | HDPE | Polyethylene |
    | Dilator Length (cm) | 47 | 40, 51 |
    | Dilator Endhole Size (in) | 0.035 | 0.035, 0.038 |
    | Catheters | | |
    | Outer Diameter (Fr) | | 5 |
    | Length (cm) | | 80 |
    | Endhole Size (in) | Not applicable | 0.035 |
    | Shaft Materials | | Teflon (Van Andel)
    Nylon (Torcon NB) |
    | | PREDICATE DEVICE | SUBJECT DEVICE |
    | | GORE TIPS Set
    (K152913) | Transjugular Liver Access Sets |
    | Wire Guides | | |
    | Wire Guide Diameter (in) | | 0.035 |
    | Wire Guide Lengths (cm) | Not applicable | 180, 190 |
    | Wire Guide Materials | | Stainless Steel
    PTFE Coating |
    | Dilator | | |
    | Dilator Outer Diameter (Fr) | | 11, 12 |
    | Dilator Length (cm) | | 20 |
    | Dilator Endhole Size (in) | Not applicable | 0.038 |
    | Dilator Shaft | | Polyethylene |
    | Dilator Hub | | HDPE |
    | Packaging/Sterilization/Shelf Life | | |
    | Packaging | Tyvek/Polyethylene-polyester
    Film | Identical |
    | Sterilization (SAL 10-6) | EtO | Identical |
    | Shelf Life | 1 year | 3 years |

6

Cook Incorporated - Traditional 510(k) Transjugular Liver Access Sets February 14, 2018

Substantial Equivalence Comparison Table (continued)

VII. PERFORMANCE DATA

The subject devices underwent the applicable testing listed below to ensure reliable design and performance under the testing parameters. Performance and biocompatibility testing was conducted in accordance with applicable FDA guidance documents to confirm the reliable performance of critical device characteristics. Testing on specific introducer and catheter components (the Van Andel Catheter, the Torcon NB® Advantage Catheter, and the Flexor Check-Flo Introducer Set) is not included because these devices have been previously cleared by the FDA under 510(k) numbers K170616, K161822, and K142829, respectively.

Biocompatibility Testing - - Per ISO 10993-1 and FDA guidance, testing for Cytotoxicity, Sensitization, Irritation, Acute Systemic Toxicity, Hemocompatibility(Hemolysis, Complement Activation, In Vivo Thrombogenicity), and Material-mediated Pyrogenicity tests were performed on all components of the subject device or on representative devices. All test results met the acceptance criteria, where applicable, or demonstrated that the device is biocompatible.

Performance Testing - The components in the subject device were subjected to applicable testing to assure reliable design and performance under the testing parameters. The tests for the core components (i.e., set components that puncture through the hepatic vein, liver parenchyma, and portal vein) and the accessories are listed below. In addition to the tests listed below, dimensional, surface and compatibility analysis was performed on all components in the subject

7

device to verify that the critical dimensions met the predefined acceptance criteria, that the surfaces of the devices were from defects, and that the set components were compatible.

Testing performed on the core components includes the following:

  • Radiopacity Testing performed demonstrated that the devices were visible in the . radiographic image and were qualitatively assessed to be non-inferior to the user-defined standard, following the method described in ASTM F640-12, "Standard Test Methods For Determining Radiopacity for Medical Use."
  • Corrosion Resistance Testing performed demonstrated that there is no effect on the . functional performance of the components.
  • Tensile Testing performed on the components per applicable ISO and JIS standards . demonstrated that the devices met the acceptance criteria.
  • . Torque - Testing performed demonstrated that the peak torque was within the clinical requirement.
  • Liquid Leakage, Air Leakage and Burst Pressure Testing performed on catheter per the . test method described in relevant annexes of ISO 10555-1:2013 met the acceptance criteria.
  • Resistance to Breakage Testing performed per the test method described in Annex C of . BS EN ISO 9626 demonstrated that the test articles met the acceptance criteria.

Testing performed on the additional set components includes the following:

  • . Dilator Hub-to-Shaft Tensile – Testing in accordance with BS EN ISO 11070 showed the peak load of the hub-to-shaft were greater than or equal to 15N.
  • Wire Guide Tensile Testing Testing in accordance with ISO 11070:2014, Annex H . showed that the pre-determined acceptance criteria were met.
  • . Wire Guide Corrosion Testing – Testing in accordance with Annex B of ISO 11070:2014 demonstrated that the pre-determined acceptance criteria were met.
  • . Wire Guide Flexing Test – Testing in accordance with the Annex G of ISO 11070:2014 demonstrated that the pre-determined acceptance criteria were met.
  • Wire Guide Fracture Testing Testing in accordance with Annex F of ISO 11070:2014 . demonstrated that the pre-determined acceptance criteria were met.
  • . Wire Guide Torque Strength Testing - Characterization testing performed in accordance with the FDA Coronary and Cerebrovascular Guidewire Guidance (1995).
  • Wire Guide Tip Flexibility Characterization testing performed in accordance with the . FDA Coronary and Cerebrovascular Guidewire Guidance (1995).

8

Cook Incorporated – Traditional 510(k) Transjugular Liver Access Sets February 14, 2018

VIII. CONCLUSIONS

The results of testing provide reasonable assurance that the Transjugular Liver Access Sets have been designed so that they conform to the requirements of their intended use. The available evidence demonstrates that the subject devices are substantially equivalent to the predicate device, the GORE TIPS Set (K152913), and do not raise new questions of safety or effectiveness. This supports a determination of substantial equivalence.